Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results

Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) announced it will release its fourth quarter and full year 2022 financial results on February 21, 2023, after trading closes. A conference call will follow at 4:30 p.m. ET, accessible via pre-registration. The call will also be webcast live on Halozyme's website.

Halozyme focuses on improving patient experiences and outcomes through its ENHANZE® technology, facilitating drug delivery and reducing treatment burdens. The company has impacted over 600,000 patients globally with its products, partnering with major pharmaceutical firms.

SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2022 financial and operating results on Tuesday, February 21, 2023, following the close of trading.

Halozyme will host a conference call on Tuesday, February 21, 2023 at 4:30 p.m. ET/1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via this link: https://conferencingportals.com/event/QfiVLXsr.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE^® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED^®, TLANDO^® and NOCDURNA^® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com

Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2022-financial-and-operating-results-301739601.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme report its fourth quarter and full year 2022 results?

Halozyme will report its fourth quarter and full year 2022 financial results on February 21, 2023.

What time is the Halozyme conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on February 21, 2023.

How can I listen to the Halozyme conference call?

You can listen to the Halozyme conference call via pre-registration at their conference link provided in the press release.

What technology does Halozyme utilize for drug delivery?

Halozyme uses the ENHANZE® technology to facilitate the delivery of injected drugs and fluids.

How many patients have benefited from Halozyme's products?

Halozyme's products have touched the lives of over 600,000 patients globally.